Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy

References

• EvansWJMorleyJEArgilésJCachexia: a new definitionClin Nutr2008276 793 79918718696
   PubMed Web of Science ®Google Scholar
• FearonKStrasserFAnkerSDDefinition and classification of cancer cachexia: an international consensusLancet Oncol2011125 489 49521296615
   PubMed Web of Science ®Google Scholar
• MondelloPMianMAloisiCFamàFMondelloSPitiniVCancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic optionsNutr Cancer2015671 12 2625513730
   PubMed Web of Science ®Google Scholar
• BruggemanARKamalAHLeBlancTWMaJDBaracosVERoelandEJCancer cachexia: beyond weight lossJ Oncol Pract20161211 1163 117127858548
   PubMed Web of Science ®Google Scholar
• JohnstonAJMurphyKTJenkinsonLTargeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs SurvivalCell20151626 1365 137826359988
   PubMed Web of Science ®Google Scholar
• SchaferMOeingCURohmMAtaxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexiaMol Metab201652 67 7826909315
   PubMed Web of Science ®Google Scholar
• PetruzzelliMWagnerEFMechanisms of metabolic dysfunction in cancer-associated cachexiaGenes Dev2016305 489 50126944676
   PubMed Web of Science ®Google Scholar
• RohmMSchäferMLaurentVAn AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in miceNat Med20162210 1120 113027571348
   PubMed Web of Science ®Google Scholar
• KirSKomabaHGarciaAPPTH/PTHrP receptor mediates cachexia in models of kidney failure and cancerCell Metab2016232 315 32326669699
   PubMed Web of Science ®Google Scholar
• MartinLSenessePGioulbasanisIDiagnostic criteria for the classification of cancer-associated weight lossJ Clin Oncol2015331 90 9925422490
   PubMed Web of Science ®Google Scholar
• DavisMPDickersonDCachexia and anorexia: cancer’s covert killerSupport Care Cancer200083 180 18710789957
   PubMed Web of Science ®Google Scholar
• VanhoutteGvan de WielMWoutersKCachexia in cancer: what is in the definition?BMJ Open Gastroenterol201631 e000097
   PubMed Web of Science ®Google Scholar
• GarberKCancer anabolic metabolism inhibitors move into clinicNat Biotechnol2016348 794 79527504761
   PubMed Web of Science ®Google Scholar
• FearonKCHArgilesJMBaracosVERequest for regulatory guidance for cancer cachexia intervention trialsJ Cachexia Sarcopenia Muscle201564 272 27426675232
   PubMed Web of Science ®Google Scholar
• MantovaniGMadedduCMaccioADrugs in development for treatment of patients with cancer-related anorexia and cachexia syndromeDrug Des Devel Ther20137 645 656
   PubMed Web of Science ®Google Scholar
• LevyMSmithTAlvarez-PerezAPalliative care version 1.2016J Natl Compr Canc Netw2016141 82 11326733557
   PubMed Web of Science ®Google Scholar
• MantovaniGMacciòAMadedduCRandomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexiaOncologist2010152 200 21120156909
   PubMed Web of Science ®Google Scholar
• MaccioAMadedduCGramignanoGA randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of lifeGynecol Oncol20121243 417 42522198049
   PubMed Web of Science ®Google Scholar
• von HaehlingSAnkerMSAnkerSDPrevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016J Cachexia Sarcopenia Muscle201675 507 50927891294
   PubMed Web of Science ®Google Scholar
• TemelJSGreerJAMuzikanskyAEarly palliative care for patients with metastatic non-small-cell lung cancerN Engl J Med20103638 733 74220818875
   PubMed Web of Science ®Google Scholar
• CuiHLopezMRahmouniKThe cellular and molecular bases of leptin and ghrelin resistance in obesityNat Rev Endocrinol2017136 338 35128232667
   PubMed Web of Science ®Google Scholar
• Al MassadiOLópezMTschöpMDiéguezCNogueirasRCurrent Understanding of the Hypothalamic Ghrelin Pathways Inducing Appetite and AdiposityTrends Neurosci2017403 167 18028108113
   PubMed Web of Science ®Google Scholar
• SunYGarciaJMSmithRGGhrelin and growth hormone secretagogue receptor expression in mice during agingEndocrinology20071483 1323 132917158206
   PubMed Web of Science ®Google Scholar
• ChenJASplenserAGuilloryBGhrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involvedJ Cachexia Sarcopenia Muscle201562 132 14326136189
   PubMed Web of Science ®Google Scholar
• PorporatoPEFilighedduNReanoSAcylated and unacylated ghrelin impair skeletal muscle atrophy in miceJ Clin Invest20131232 611 62223281394
   PubMed Web of Science ®Google Scholar
• GarciaJMSwerdloffRWangCMacimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiencyJ Clin Endocrinol Metab2013986 2422 242923559086
   PubMed Web of Science ®Google Scholar
• Foster-SchubertKECummingsDEEmerging therapeutic strategies for obesityEndocr Rev2006277 779 79317122357
   PubMed Web of Science ®Google Scholar
• HaslerWLEmerging drugs for the treatment of gastroparesisExpert Opin Emerg Drugs2014192 261 27924669936
   PubMed Web of Science ®Google Scholar
• DeBoerMDZhuXXLevasseurPGhrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexiaEndocrinology20071486 3004 301217347304
   PubMed Web of Science ®Google Scholar
• DixitVDSchafferEMPyleRSGhrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cellsJ Clin Invest20041141 57 6615232612
   PubMed Web of Science ®Google Scholar
• HiuraYTakiguchiSYamamotoKEffects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 studyCancer201211819 4785 479422282373
   PubMed Web of Science ®Google Scholar
• NearyNMSmallCJWrenAMGhrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trialJ Clin Endocrinol Metab2004896 2832 283615181065
   PubMed Web of Science ®Google Scholar
• NagayaNMoriyaJYasumuraYEffects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failureCirculation200411024 3674 367915569841
   PubMed Web of Science ®Google Scholar
• MikiKMaekuraRNagayaNGhrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trialPLoS One201275 e3570822563468
   PubMed Web of Science ®Google Scholar
• NagayaNItohTMurakamiSTreatment of cachexia with ghrelin in patients with COPDChest20051283 1187 119316162705
   PubMed Web of Science ®Google Scholar
• KojimaMHosodaHDateYNakazatoMMatsuoHKangawaKGhrelin is a growth-hormone-releasing acylated peptide from stomachNature19994026762 656 66010604470
   PubMed Web of Science ®Google Scholar
• BowersCYMomanyFReynoldsGAChangDHongAChangKStructure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitroEndocrinology19801063 663 6677353536
   PubMed Web of Science ®Google Scholar
• HansenTKPeschkeBLauJLundtBFAnkersenMWatsonBMadsenKinventorsNovo Nordisk A/S, asigneeCompounds with growth hormone releasing propertiesUnited States patent US61273911032000
   Google Scholar
• BednarekMAFeighnerSDPongSSStructure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1aJ Med Chem20004323 4370 437611087562
   PubMed Web of Science ®Google Scholar
• LeesePTTrangJMBlumRAde GrootEAn open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelinClin Pharmacol Drug Dev201542 112 12026640742
   PubMed Web of Science ®Google Scholar
• PietraCTakedaYTazawa-OgataNAnamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profileJ Cachexia Sarcopenia Muscle201454 329 33725267366
   PubMed Web of Science ®Google Scholar
• NorthrupRKurodaKDuusEMEffect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft modelSupport Care Cancer2013219 2409 241523579947
   PubMed Web of Science ®Google Scholar
• GarciaJMPolvinoWJPharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteersGrowth Horm IGF Res2009193 267 27319196529
   PubMed Web of Science ®Google Scholar
• GarciaJMPolvinoWJEffect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteersOncologist2007125 594 60017522248
   PubMed Web of Science ®Google Scholar
• GarciaJMFriendJAllenSTherapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot studySupport Care Cancer2013211 129 13722699302
   PubMed Web of Science ®Google Scholar
• GarciaJMBocciaRVGrahamCDAnamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trialsLancet Oncol2015161 108 11625524795
   PubMed Web of Science ®Google Scholar
• TakayamaKKatakamiNYokoyamaTAnamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trialSupport Care Cancer2016248 3495 350527005463
   PubMed Web of Science ®Google Scholar
• TemelJSAbernethyAPCurrowDCAnamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trialsLancet Oncol2016174 519 53126906526
   PubMed Web of Science ®Google Scholar